Pontiggia P, Ogier C, Follini G D
Blut. 1983 Sep;47(3):153-6. doi: 10.1007/BF00320177.
The effect of the calf thymus extract thymustimulin (Tp-1) on lymphocyte subpopulations of 12 patients affected by lymphoproliferative disorders with low T-cell level was studied. T and B cells of four patients with non-Hodgkin lymphoma, three with Hodgkin's disease, one with myeloma and four with chronic lymphatic leukemia were evaluated before and after treatment for 3 months with Tp-1. The total number and the percentage of T-cells increased significantly (p less than 0.05) in patients with non Hodgkin lymphoma, Hodgkin's disease and myeloma and only numerically in patients with chronic lymphatic leukemia, while no significant change of the total WBC count and of the total number and percentage of B-cells occurred in any patients. These results suggest that Tp-1 treatment might be effective in restoring immunocompetence in patients with T-cell deficiency secondary to lymphoproliferative disorders.
研究了小牛胸腺提取物胸腺刺激素(Tp-1)对12例T细胞水平低下的淋巴增殖性疾病患者淋巴细胞亚群的影响。对4例非霍奇金淋巴瘤、3例霍奇金病、1例骨髓瘤和4例慢性淋巴细胞白血病患者在接受Tp-1治疗3个月前后的T细胞和B细胞进行了评估。非霍奇金淋巴瘤、霍奇金病和骨髓瘤患者的T细胞总数和百分比显著增加(p<0.05),慢性淋巴细胞白血病患者仅略有增加,而所有患者的白细胞总数、B细胞总数和百分比均无显著变化。这些结果表明,Tp-1治疗可能有效恢复继发于淋巴增殖性疾病的T细胞缺乏患者的免疫能力。